Cargando…

EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells

The adverse prognosis of most patients with ovarian cancer is related to recurrent disease caused by resistance to chemotherapeutic and targeted therapeutics. Besides their direct activity against tumor cells, monoclonal antibodies and tyrosine kinase inhibitors (TKIs) also influence the antitumoral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mallmann-Gottschalk, Nina, Sax, Yvonne, Kimmig, Rainer, Lang, Stephan, Brandau, Sven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801374/ https://www.ncbi.nlm.nih.gov/pubmed/31546690 http://dx.doi.org/10.3390/ijms20194693

Ejemplares similares

Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity
por: Gottschalk, Nina, et al.
Publicado: (2012)

Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites
por: Hrvat, Antonio, et al.
Publicado: (2023)

Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines
por: Gottschalk, Nina, et al.
Publicado: (2012)

Reactivity of NK Cells Against Ovarian Cancer Cells Is Maintained in the Presence of Calcium Phosphate Nanoparticles
por: Hrvat, Antonio, et al.
Publicado: (2022)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer
por: Greppi, Marco, et al.
Publicado: (2019)

EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
por: Schuler, Patrick J, et al.
Publicado: (2011)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
por: Shi, Chen, et al.
Publicado: (2023)

Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
Publicado: (2019)

Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function
por: Damele, Laura, et al.
Publicado: (2018)

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
por: Thomas, Rintu, et al.
Publicado: (2019)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
por: Diaz, Roque, et al.
Publicado: (2010)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
por: Boonsri, Boonyakorn, et al.
Publicado: (2021)

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
por: Smith, Donald L., et al.
Publicado: (2014)

ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer
por: Azuma, Koichi, et al.
Publicado: (2018)

Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
por: Li, Xin, et al.
Publicado: (2018)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma
por: Vatte, Chittibabu, et al.
Publicado: (2017)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
por: Hirokawa, Esuteru, et al.
Publicado: (2021)

Epigenetic Regulation of NK Cell-Mediated Antitumor Immunity
por: Xia, Miaoran, et al.
Publicado: (2021)

Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
por: Gandhi, Jeet, et al.
Publicado: (2009)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
por: Tabara, Keisuke, et al.
Publicado: (2012)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
por: Wang, Jun, et al.
Publicado: (2016)

Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
por: Vouri, M, et al.
Publicado: (2016)

Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
por: Rodrigues-Santos, Paulo, et al.
Publicado: (2018)

Synthesis, Molecular Dynamics Simulation, and In-vitro Antitumor Activity of Quinazoline-2,4,6-triamine Derivatives as Novel EGFR Tyrosine Kinase Inhibitors
por: Nili Ahmadabadi, Maryam, et al.
Publicado: (2023)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Sirinian, Chaido, et al.
Publicado: (2021)

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
por: Masuda, Takeshi, et al.
Publicado: (2023)

Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
por: Krawczyk, Paweł, et al.
Publicado: (2012)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_70fj7vvbllgi2sv115iudqdl7r